Rational experimental design for bioanalytical methods validation - Illustration using an assay method for total captopril in plasma

被引:54
作者
Wieling, J [1 ]
Hendriks, G [1 ]
Tamminga, WJ [1 ]
Hempenius, J [1 ]
Mensink, CK [1 ]
Oosterhuis, B [1 ]
Jonkman, JHG [1 ]
机构
[1] PHARMA BIORES INT BV,NL-9471 GP ZUIDLAREN,NETHERLANDS
关键词
validation; experimental design; pharmaceutical analysis; chemometrics; captopril; paracetamol;
D O I
10.1016/0021-9673(96)00006-4
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Generally, bioanalytical chromatographic methods are validated according to a predefined programme and distinguish a pre-validation phase, a main validation phase and a follow-up validation phase. In this paper, a rational, total performance evaluation programme for chromatographic methods is presented. The design was developed in particular for the pre-validation and main validation phases. The entire experimental design can be performed within six analytical runs. The first run (pre-validation phase) is used to assess the validity of the expected concentration-response relationship (lack of fit, goodness of fit), to assess the specificity of the method and to assess the stability of processed samples in the autosampler for 30 h (benchtop stability). The latter experiment is performed to justify overnight analyses. Following approval of the method after the pre-validation phase, the next five runs (main validation phase) are performed to evaluate method precision and accuracy, recovery, freezing and thawing stability and over-curve control/dilution. The design is nested, i.e., many experimental results are used for the evaluation of several performance characteristics. Analysis of variance (ANOVA) is used for the evaluation of lack of fit and goodness of fit, precision and accuracy, freezing and thawing stability and over-curve control/dilution. Regression analysis is used to evaluate benchtop stability. For over-curve control/dilution, additional to ANOVA, also a paired comparison is applied. As a consequence, the recommended design combines the performance of as few independent validation experiments as possible with modern statistical methods, resulting in optimum use of information. A demonstration of the entire validation programme is given for an HPLC method for the determination of total captopril in human plasma.
引用
收藏
页码:381 / 394
页数:14
相关论文
共 14 条
[1]   METHOD VALIDATION IN THE BIOANALYTICAL LABORATORY [J].
BUICK, AR ;
DOIG, MV ;
JEAL, SC ;
LAND, GS ;
MCDOWALL, RD .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1990, 8 (8-12) :629-637
[2]  
*CIB GEIG, 1980, GEIG SCI TABL STAT
[3]  
DAGDAR D, 1995, J PHARM BIOMED ANAL, V13, P89
[4]   PHARMACOKINETICS OF CAPTOPRIL IN HEALTHY-SUBJECTS AND IN PATIENTS WITH CARDIOVASCULAR-DISEASES [J].
DUCHIN, KL ;
MCKINSTRY, DN ;
COHEN, AI ;
MIGDALOF, BH .
CLINICAL PHARMACOKINETICS, 1988, 14 (04) :241-259
[5]  
*FDA, 1978, GOOD LAB PRACT NONCL
[6]   EXTENSION OF SAMPLE SIZES AND PERCENTAGE POINTS FOR SIGNIFICANCE TESTS OF OUTLYING OBSERVATIONS [J].
GRUBBS, FE ;
BECK, G .
TECHNOMETRICS, 1972, 14 (04) :847-&
[7]   AN ANALYSIS OF THE WASHINGTON CONFERENCE REPORT ON BIOANALYTICAL METHOD VALIDATION [J].
HARTMANN, C ;
MASSART, DL ;
MCDOWALL, RD .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1994, 12 (11) :1337-1343
[8]   A COMPREHENSIVE METHOD VALIDATION STRATEGY FOR BIOANALYTICAL APPLICATIONS IN THE PHARMACEUTICAL-INDUSTRY .1. EXPERIMENTAL CONSIDERATIONS [J].
LANG, JR ;
BOLTON, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (05) :357-361
[9]   A COMPREHENSIVE METHOD VALIDATION STRATEGY FOR BIOANALYTICAL APPLICATIONS IN THE PHARMACEUTICAL-INDUSTRY .2. STATISTICAL-ANALYSES [J].
LANG, JR ;
BOLTON, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1991, 9 (06) :435-442
[10]  
*OECD, 1982, GOOD LAB PRACT TEST